BioAdvance, the operator of a $50 million early stage life sciences fund that work with health-care entrepreneurs in the mid-Atlantic region, invested $2.9 million in companies and technologies targeting human health during fiscal 2016

The investments, according to a report released late Tuesday by BioAdvance, included nine new companies and technologies plus six follow-on investments of exiting portfolio companies.

Image: BioAdvance CEO Barbara Schilberg